PT1121135E - Composições de b-glucanos e de imunoglobulinas específicas - Google Patents

Composições de b-glucanos e de imunoglobulinas específicas Download PDF

Info

Publication number
PT1121135E
PT1121135E PT99969030T PT99969030T PT1121135E PT 1121135 E PT1121135 E PT 1121135E PT 99969030 T PT99969030 T PT 99969030T PT 99969030 T PT99969030 T PT 99969030T PT 1121135 E PT1121135 E PT 1121135E
Authority
PT
Portugal
Prior art keywords
glucan
specific
antibodies
antigen
glucans
Prior art date
Application number
PT99969030T
Other languages
English (en)
Portuguese (pt)
Inventor
Ali Ibrahim Fattom
Robert B Naso
Viliam Pavliak
Original Assignee
Nabi Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi Biopharmaceuticals filed Critical Nabi Biopharmaceuticals
Publication of PT1121135E publication Critical patent/PT1121135E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PT99969030T 1998-09-14 1999-09-14 Composições de b-glucanos e de imunoglobulinas específicas PT1121135E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10014698P 1998-09-14 1998-09-14

Publications (1)

Publication Number Publication Date
PT1121135E true PT1121135E (pt) 2009-03-05

Family

ID=22278313

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99969030T PT1121135E (pt) 1998-09-14 1999-09-14 Composições de b-glucanos e de imunoglobulinas específicas

Country Status (11)

Country Link
US (1) US6355625B1 (de)
EP (1) EP1121135B1 (de)
AT (1) ATE421883T1 (de)
AU (1) AU6033299A (de)
CA (1) CA2344166C (de)
CY (1) CY1109437T1 (de)
DE (1) DE69940371D1 (de)
DK (1) DK1121135T3 (de)
ES (1) ES2321892T3 (de)
PT (1) PT1121135E (de)
WO (1) WO2000015238A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US7030101B2 (en) * 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2002058711A1 (en) 2001-01-16 2002-08-01 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
WO2004030613A2 (en) * 2002-09-04 2004-04-15 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
CN1964722A (zh) * 2004-05-10 2007-05-16 生物聚合物工程有限公司 与抗生素、疫苗和病毒单克隆抗体组合的全葡聚糖颗粒
KR101505496B1 (ko) 2004-09-22 2015-03-25 글락소스미스클라인 바이오로지칼즈 에스.에이. 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성 조성물
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
US20060153857A1 (en) * 2005-01-10 2006-07-13 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
US20070059310A1 (en) * 2005-05-03 2007-03-15 Karel Steven J Therapeutic combination compositions and methods of using same
CA2912012C (en) * 2005-05-05 2018-05-29 Sensient Flavors Inc. Production of beta-glucans and mannans
US20090074755A1 (en) 2005-06-13 2009-03-19 Nabi Biopharmaceuticals Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
JP2009531387A (ja) 2006-03-30 2009-09-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
CA2655133C (en) 2006-06-12 2018-03-20 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
EP2208787A1 (de) 2009-01-19 2010-07-21 Université de Liège Rekombinantes alpha-Hämolysin-Polypeptid von Staphylococcus aureus, mit einer Deletion in der Stammdomäne und eingefügten heterologen Sequenzen
WO2010085590A1 (en) 2009-01-23 2010-07-29 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria
EP3281947B1 (de) 2009-04-03 2020-02-12 The University of Chicago Zusammensetzungen und verfahren in verbindung mit protein-a (spa)-varianten
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
US8808699B2 (en) 2010-04-05 2014-08-19 The University Of Chicago Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
HRP20220068T1 (hr) 2010-05-05 2022-04-15 New York University Staphylococcus aureus leukocidini, terapijski pripravci, i njihova uporaba
SG186290A1 (en) 2010-07-02 2013-01-30 Univ Chicago Compositions and methods related to protein a (spa) variants
EP2614074A1 (de) 2010-09-09 2013-07-17 The University of Chicago Verfahren und zusammensetzungen mit schützenden staphylokokken-antigenen
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
LT3403669T (lt) 2011-06-19 2020-10-12 New York University Staphylococcus aureus infekcijų ir giminingų būklių gydymo bei prevencijos būdai
EP2720754B1 (de) 2011-06-19 2016-10-19 New York University Leukotoxin e/d als neue entzündungshemmer und mikrobizide
EP2744517B1 (de) 2011-08-15 2019-03-13 The University of Chicago Zusammensetzungen und verfahren in zusammenhang mit antikörpern gegen das staphylokokken-protein a
CN104703622B (zh) 2012-04-26 2017-05-24 芝加哥大学 与金黄色葡萄球菌疾病期间抵消凝固酶活性的抗体相关的组合物和方法
US9968668B2 (en) 2012-04-26 2018-05-15 The University Of Chicago Staphylococcal coagulase antigens and methods of their use
WO2013165593A1 (en) * 2012-04-30 2013-11-07 Biothera, Inc. COMPOSITIONS AND METHODS FOR β-GLUCAN IMMUNOTHERAPY
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
EP3229833A1 (de) 2014-12-10 2017-10-18 GlaxoSmithKline Biologicals SA Behandlungsverfahren
AU2017218768B2 (en) 2016-02-12 2022-03-31 Janssen Pharmaceuticals, Inc. Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
CN115151559A (zh) 2019-10-02 2022-10-04 扬森疫苗与预防公司 葡萄球菌肽和使用方法
WO2023192998A1 (en) 2022-04-01 2023-10-05 Icahn School Of Medicine At Mount Sinai Treating orthopedic injury with a vector driving expression of acid ceramidase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900722A (en) * 1985-08-19 1990-02-13 Bioglucans, L.P. Methods and compositions for prophylactic and therapeutic treatment of infections
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
CA2040374C (en) * 1990-07-06 1998-06-16 Gunnar Rorstad Process for enhancing the resistance of aquatic animals to disease
ES2198405T3 (es) * 1991-11-22 2004-02-01 Nabi Biopharmaceuticals Antigenos de superficie de tipo i asociados a staphylococcus epidermis.
WO1996014873A2 (en) * 1994-11-16 1996-05-23 Sri International COVALENTLY BOUND β-GLUCAN CONJUGATES IN TARGETED DELIVERY
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen

Also Published As

Publication number Publication date
ATE421883T1 (de) 2009-02-15
AU6033299A (en) 2000-04-03
EP1121135A4 (de) 2005-03-16
DK1121135T3 (da) 2009-03-23
CA2344166A1 (en) 2000-03-23
CY1109437T1 (el) 2014-08-13
EP1121135B1 (de) 2009-01-28
WO2000015238A9 (en) 2000-10-12
DE69940371D1 (de) 2009-03-19
WO2000015238A1 (en) 2000-03-23
WO2000015238B1 (en) 2000-08-31
EP1121135A1 (de) 2001-08-08
CA2344166C (en) 2008-11-18
US6355625B1 (en) 2002-03-12
ES2321892T3 (es) 2009-06-12

Similar Documents

Publication Publication Date Title
PT1121135E (pt) Composições de b-glucanos e de imunoglobulinas específicas
US8591910B2 (en) Chemically programmable immunity
Stein et al. Neonatal administration of idiotype or antiidiotype primes for protection against Escherichia coli K13 infection in mice.
Young et al. Monoclonal antibodies for treatment of gram-negative infections
US5770208A (en) Staphylococcus aureus B-linked hexosamine antigen
EP0630260B1 (de) Konjugate bestehend aus polysaccharid und protein
JP2009227680A (ja) 腸球菌抗原およびワクチン
PT2445522T (pt) Composições imunogénicas de antigénios de staphylococcus aureus
Hemachandra et al. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis
JPH0545570B2 (de)
US7030101B2 (en) Compositions of β-glucans and specific antibodies
DECKERS et al. Transfer of immunity to tumour isografts by the systemic administration of xenogeneic “immune” RNA
ES2366735B1 (es) Vacuna frente a acinetobacter baumannii.
Fattom et al. Staphylococcal vaccines: a realistic dream
US3674863A (en) Polyvalent immunizing agents and methods for their production
Holt et al. Studies of the protective effect of different fractions of sera from pigs immune to Streptococcus suis type 2 infection
Pennington et al. Efficacy of intravenous immune globulin for treatment of experimental Pseudomonas aeruginosa pneumonia
MXPA01002668A (en) COMPOSITIONS OF&bgr;-GLUCANS AND SPECIFIC IGIV
JPH02502423A (ja) 連鎖球菌属に対する抗体
Cooper Solid phase activators of the alternative pathway of complement and their use in vivo
US4414201A (en) Immunopotentiator containing abrin
Cameron Antiphagocytic activity of Staphylococcus aureus antigens
Satomi et al. Traditional Chinese medicines and drugs in relation to the host-defense mechanism
WO1990013660A2 (en) Human monoclonal antibodies to sero-specific determinants of gram-negative bacteria
Gross et al. The" Antiendotoxic" Action of Certain Organic Sulfur Compounds with Review of the Theories of the Mechanism of Action of the Sulfonamide Compounds